Introduction
CML
CHRONIC MYELOID LEUKEMIA, CML
Tyrosine kinase inhibitors (TKIs) targeting the ABL and BCR::ABL1 adenosine triphosphate (ATP) binding sites have significantly extended the lives of patients with chronic myeloid leukemia (CML) [As patients without satisfactory treatment outcomes advance through successive lines of TKIs, treatment failure rates increase, survival rates decrease [Asciminib is the first BCR::ABL1 inhibitor that specifically targets the ABL myristoyl pocket (STAMP), allosterically restoring inhibition of the ABL1 kinase [Prior analysis from this phase 1 trial after a median follow-up of 14 months first provided safety and efficacy data for asciminib in patients with CML-CP/AP with or without T315I [